Any current/future new fundraising through debt or equity?

The INR350 crore QIP raised is planned to cover the company's funding needs for the next two financial years (FY’26–27 and FY’27–28). No additional external funding is anticipated during this period. Beyond these two years, as a large number of stores mature and generate strong internal cash flows, future funding requirements may significantly reduce or may not arise at all. The company has no current plans for further equity fundraising such as QIPs or IPOs (including for its subsidiary Davaindia). The current priority is to support growth through internal accruals and operational cas

Any current/future capex/capital investment/strategic investment?

The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia. Majority of the funds are used for new store expansions and working capital requirements within Davaindia. A smaller portion of the QIP funds is allocated to General Corporate Purposes. The company has incorporated a new wholly owned subsidiary, KMHP Ventures Limited, to engage in marketing and trading of pharmaceutical products, enhancing control over sourcing, distribution, and margin optimization. Additional equity has been infused in Davaindia Health Mart Limited to support COCO store expansion and work

Future growth expectations in sales/revenue/volumes?

Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. Gross margins have improved YoY from 55% to nearly 60%, driven by higher Davaindia revenue contribution. Blended EBITDA margin at consolidated level expected to improve to 15%-20% over 2-3 years if no new stores added, reflecting maturation of existing stores. Planned aggressive expansion with 800-1,000 new COCO stores annually; next year's store addition to be more evenly phased (~200-250 per quarter). Footfalls

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added. Mature stores, even first cohort stores, are witnessing 15%-20% year-on-year growth in revenues, with potential to cross INR1 crore per store per annum in 2 years. Gross margins have improved from 55% to nearly 60% year-on-year, driven by higher contribution from Davaindia revenues, supporting margin expansion. Future revenue growth will be supported by steady store add

IN US

Sale is live|00:00:00left today

Zota Health Care LtdQ4 FY27Pharmaceuticals & Biotechnology

Zota Health Care Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,390Market Cap: ₹4.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years.
→Gross margins have improved YoY from 55% to nearly 60%, driven by higher Davaindia revenue contribution.
→Blended EBITDA margin at consolidated level expected to improve to 15%-20% over 2-3 years if no new stores added, reflecting maturation of existing stores.
→Planned aggressive expansion with 800-1,000 new COCO stores annually; next year's store addition to be more evenly phased (~200-250 per quarter).
→Footfalls at mature stores rising (80-100 daily customers for >2 years stores), with overall footfall stable despite new low-traffic stores.
→Employee and marketing costs expected to normalize in 1-2 quarters as expansion pipeline steadies.
→Internal cash flow generation expected to reduce future funding needs post-2028-29 as stores mature.

Margin guidance

Category 1

→EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.
→Mature stores, even first cohort stores, are witnessing 15%-20% year-on-year growth in revenues, with potential to cross INR1 crore per store per annum in 2 years.
→Gross margins have improved from 55% to nearly 60% year-on-year, driven by higher contribution from Davaindia revenues, supporting margin expansion.
→Future revenue growth will be supported by steady store additions (200-250 stores quarterly), with a mix of mature and new stores leading to more stable costs and margins.
→Internal cash generation is expected to increase as a large number of stores mature, possibly reducing funding needs beyond FY27–28.
→Overall, growth in earnings/operating profits and EPS is expected to be strong over the medium term, driven by store maturity and improved margins.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The INR350 crore QIP raised is planned to cover the company's funding needs for the next two financial years (FY’26–27 and FY’27–28).
→No additional external funding is anticipated during this period.
→Beyond these two years, as a large number of stores mature and generate strong internal cash flows, future funding requirements may significantly reduce or may not arise at all.
→The company has no current plans for further equity fundraising such as QIPs or IPOs (including for its subsidiary Davaindia).
→The current priority is to support growth through internal accruals and operational cash flows, reducing reliance on external funding going forward.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Zota Healthcare Limited. However, some relevant points related to store expansion and order pipeline include: - For the current financial year, the company targeted opening 800 COCO stores, with 355 stores opened in the first two quarters. - In Q3, they front-loaded store additions, putting over 500 stores into the pipeline for accelerated execution. - Moving forward, store additions are expected to be evenly phased with 200-250 stores put into process each quarter. - For next year, a similar target of 800 to 1,000 store openings is expected. - Around 70% of the stores in the current pipeline (400 stores) are expected to open within the quarter. These indicate an active and sizable order pipeline primarily focused on store expansion.

Capex plans

Yes

→The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
→Majority of the funds are used for new store expansions and working capital requirements within Davaindia.
→A smaller portion of the QIP funds is allocated to General Corporate Purposes.
→The company has incorporated a new wholly owned subsidiary, KMHP Ventures Limited, to engage in marketing and trading of pharmaceutical products, enhancing control over sourcing, distribution, and margin optimization.
→Additional equity has been infused in Davaindia Health Mart Limited to support COCO store expansion and working capital.
→The company acquired 100% equity stake in Curexis, a retail pharmacy platform operating the “SKIA” brand, broadening their portfolio in pharmaceuticals, nutraceuticals, cosmetics, Ayurvedic, and OTC products.
→Focus remains on scaling the Davaindia network to cross 5,000 stores by March 2029 with a sharper focus on unit economics and operating efficiencies.

How does Zota Health Care Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zota Health Care Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zota Health Care Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio